Peter Attia· MD
and they found that NP if you look at people who report eating less than 1.5 fish meals a week there was a significant staff it on the primary endpoint of cardiovascular disease both taking just one capsule Lovaza
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
and they found that NP if you look at people who report eating less than 1.5 fish meals a week there was a significant staff it on the primary endpoint of cardiovascular disease both taking just one capsule Lovaza
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
heart attacks were significantly you know 20% reduction in heart attacks and 20% reduction in fatal heart attacks were one of the findings I mean that's impressive for 850 milligrams a day it's amazing to me that you can even do that now
so i think it was a positive study at the end of the day and and that study itself kind of proves because it because it was laveza which is the epa aj combo that dha can't be negating any because i suppose the other side can say well it's yeah it would have been much better if it was just epa right
if you look at the individual elements there was benefit there was reduced major reduction risk of heart attack and even in people who didn't who were eight little fish or half the lower half of the fish intake they got a significant reduction in the primary endpoint right
Um and particularly people this was happening in people that were having a low fish intake. So we have I think a lot of evidence that omega-3 is very important for cardiovascular health and it doesn't take a lot of omega-3.
We have the vital study where people were actually given a low dose. They were given like 800 milligrams of uh Lovesa. So that's the pres prescription form of omega-3. That's EPA and DHA. Um, if we look at secondary outcomes, these individuals had about a 30% lower um uh heart attack risk compared to placebo. This was a 5-year study.
In this trial, they were only given 840 milligrams of Levvesa, which is a combination of both EPA and DHA, or they were given a placebo control. And this was also a 5-year trial. After the five years, some of the secondary outcomes that were looked at were actually improved with respect to cardiovascular health. So individuals that were given the the prescription in Luvvesa had a 28% lower heart attack risk and they had a 17% lower coronary artery disease risk compared to those given a placebo and that was at a pretty low dose.